52 completed, 3 terminated, 3 unknown, 1 not yet recruiting. 31 Phase 3, 11 Phase 2, 9 Phase 4, 5 Phase 1, 2 Not applicable.
By phase and status
Follow alogliptin: new trials by email Literature Review of alogliptin trials Research Report on alogliptin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
The Effect of Alogliptin Combined With Actoplus Met on Glucose and Lipid Metabolism and Pancreatic Function in Patients With T2DM Complicated With MAFLD alogliptin and actoplus met, actoplus met - T2DM, MAFLD Phase 4 Not yet recruiting The Fourth Affiliated Hospital of Zhejiang University School of Medicine 80 2026-05-01 2026-03-24 Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin Metformin, Alogliptin, empagliflozin - T2DM, Diabete Type 2 Phase 3 Recruiting Celltrion 171 2025-07-18 2025-08-11 Comparison of Type 2 Diabetes Pharmacotherapy Regimens SU, DPP4, SGLT2i - Type 2 Diabetes Mellitus, Cardiovascular Diseases Completed Kaiser Permanente 241981 2021-07-01 2025-11-21 A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin Therapy Pioglitazone + Alogliptin, Alogliptin, Metformin - Diabetes Mellitus, Type 2 Phase 4 Completed Celltrion Pharm, Inc. 133 2020-02-11 2026-03-18 Efficacy and Safety of Alogliptin vs. Acarbose in Chinese Type 2 Diabetes Mellitus (T2DM) Patients With High CV Risk or CHD Treated With Aspirin and Inadequately Controlled With Metformin Monotherapy or Drug Naive Alogliptin, Acarbose, Metformin - Type 2 Diabetes Mellitus Phase 4 Completed Sanofi 1293 2019-06-29 2022-04-25 SAL067 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise SAL067, Alogliptin, Placebo - Diabetes Mellitus, Type 2 Phase 3 Completed Shenzhen Salubris Pharmaceuticals Co., Ltd. 458 2019-06-13 2023-03-23 A Study to Determine the Bioequivalence of Alogliptin and Pioglitazone When Administered as Individual Tablets and as Fixed-Dose Combination (FDC)-SYR-322-4833 BL Tablets to Healthy Russian Participants Alogliptin, Pioglitazone, SYR-322-4833 BL - Healthy Volunteers Phase 1 Completed Takeda 72 2018-05-26 2019-08-08 Treatment Preference for Weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Versus Daily DPP-4 Inhibitors in Participants With Type 2 Diabetes Mellitus Trelagliptin, Alogliptin - Type 2 Diabetes Mellitus Phase 4 Completed Takeda 60 2017-08-18 2023-12-22 Safety and Efficacy of Alogliptin in Indian Participants With Type 2 Diabetes Mellitus Alogliptin - Diabetes Mellitus, Type 2 Phase 4 Withdrawn Takeda 2017-07-30 2017-10-20 Specified Drug-Use Survey of Alogliptin and Metformin Hydrochloride Combination Tablets "Survey on Long-term Use in Type 2 Diabetes Mellitus Patients With Renal or Hepatic Impairment or Advanced Age" Alogliptin and Metformin hydrochloride - Type 2 Diabetes Mellitus Completed Takeda 1026 2017-02-28 2023-09-13 Non-Interventional Study of the Use of Alogliptin and Alogliptin Fixed-Dose Combinations With Pioglitazone and With Metformin in Standard Clinical Practice Alogliptin, Alogliptin FDC With Pioglitazone, Alogliptin FDC With Metformin - Diabetes Mellitus, Type 2 Terminated Takeda 593 2016-12-22 2019-04-19 Phase 3 Alogliptin Pediatric Study Alogliptin Benzoate, Placebo - Diabetes Mellitus, Type 2 Phase 3 Completed Takeda 152 2016-10-14 2022-10-19 An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes Mellitus Trelagliptin, Alogliptin - Type 2 Diabetes Mellitus Phase 4 Completed Takeda 27 2016-09-08 2023-12-12 An Extension Study of PEAK Trial alogliptin+pioglitazone, alogliptin, pioglitazone - Diabetes Mellitus, Type 2 Phase 4 Terminated Kun-Ho Yoon 41 2016-05-18 2019-06-05 Phase 1 Bioavailability Study of SYR-322MET Alogliptin, Metformin Hydrochloride, SYR-322MET - Healthy Volunteers Phase 1 Completed Takeda 24 2016-04-01 2016-10-05 Glimepiride, Alogliptin and Alogliptin+Pioglitazone Combination Glimepiride, Alogliptin 25Mg Tab, Alogliptin-Pioglitazone 25 Mg-15 Mg Oral Tablet - Type 2 Diabetes Mellitus Phase 4 Unknown Seoul National University Hospital 99 2015-12-31 2020-10-22 The Practical Evidence of Antidiabetic Combination Therapy in Korea alogliptin, Pioglitazone, alogliptin + pioglitazone - Type 2 Diabetes Mellitus Phase 4 Completed Kun-Ho Yoon 216 2014-09-01 2019-02-08 Alogliptin Tablets Specified Drug-use Survey "Type 2 Diabetic Patients Receiving Combination Therapy With a Hypoglycemic Agent (e.g., Insulin Preparations or Rapid-acting Insulin Secretagogues)" Alogliptin - Type 2 Diabetes Mellitus Completed Takeda 964 2014-06-30 2019-11-06 The Effect of Alogliptin on Pulmonary Function in Obese Patients With Type 2 Diabetes Inadequately Controlled by Metformin Monotherapy Alogliptin and Metformin - Diabetes Mellitus, Type 2 Not applicable Completed Fourth People's Hospital of Shenyang 81 2014-05-01 2016-06-14 A Study for Post-Marketing Surveillance of Nesina® Tablet Monotherapy or Combination Therapy in Participants With Type 2 Diabetes (T2DM) in South Korea Alogliptin Benzoate - Type 2 Diabetes Mellitus Completed Takeda 3623 2014-04-19 2022-04-05
Showing 20 of 61. Sign in to see all of them.
Conditions studied Diabetes Mellitus, Type 2 (51) · Diabetes Mellitus (28) · Glucose Metabolism Disorders (13) · Dyslipidemias (11) · Hyperglycemia (4) · Diabetes Mellitus, Lipoatrophic (3) · Glucose Intolerance (2) · Hyperinsulinism (2) · Metabolic Diseases (2) · Acute Coronary Syndrome (1) · Cardiovascular Diseases (1) · Endocrine System Diseases (1) · Hypoglycemia (1) · Insulin Resistance (1) · Myocardial Infarction (1)
Sponsors Takeda (47) · Kun-Ho Yoon (2) · Aichi Gakuin University (1) · Astellas Pharma Inc (1) · AstraZeneca (1) · Celltrion (1) · Celltrion Pharm, Inc. (1) · Fourth People's Hospital of Shenyang (1) · Kaiser Permanente (1) · Nagaoka Red Cross Hospital (1) · Sanofi (1) · Seoul National University Hospital (1) · Shenzhen Salubris Pharmaceuticals Co., Ltd. (1) · The Fourth Affiliated Hospital of Zhejiang University School of Medicine (1)
Countries United States (17) · Japan (16) · Mexico (12) · South Africa (12) · Brazil (11) · Poland (11) · Guatemala (10) · India (10) · Peru (10) · Argentina (9) · Australia (9) · Chile (9) · Hungary (9) · New Zealand (9) · South Korea (9)
Top investigators Kun-Ho Yoon, MD, PhD (2) · Kyuzi Kamoi, MD (1) · Li Yan, Ph.D (1) · Patrick J O'Connor, MD, MA, MPH (1)
Results publications PMID 19793357 , PMID 22106975 , PMID 24843617 , PMID 18809631 , PMID 19125778 , PMID 19125992 , PMID 19650752 , PMID 19758359 , PMID 20724648 , PMID 21733058 , PMID 21982652 , PMID 22237690 , PMID 22419732 , PMID 23992602 , PMID 24400655 , PMID 25190226 , PMID 25609193 , PMID 25765696 , PMID 27289121 , PMID 27787778 , PMID 28246236 , PMID 28275958 , PMID 29064626 , PMID 29581078 , PMID 29769203 , PMID 29848776 , PMID 30371278 , PMID 31366262 , PMID 31562608 , PMID 31902327 , PMID 32493335 , PMID 34872085 , PMID 37814306 , PMID 38745886 , PMID 38837240 , PMID 40032809 , PMID 40734551 , PMID 41091469
NIH funding 2005 (6), 2009 (3), 2008 (2), 2015 (1)